[go: up one dir, main page]

AR088511A1 - Derivados heterociclicos como moduladores de trpv3 - Google Patents

Derivados heterociclicos como moduladores de trpv3

Info

Publication number
AR088511A1
AR088511A1 ARP120103976A ARP120103976A AR088511A1 AR 088511 A1 AR088511 A1 AR 088511A1 AR P120103976 A ARP120103976 A AR P120103976A AR P120103976 A ARP120103976 A AR P120103976A AR 088511 A1 AR088511 A1 AR 088511A1
Authority
AR
Argentina
Prior art keywords
cr1ar1b
alkyl
haloalkyl
independently
halogen
Prior art date
Application number
ARP120103976A
Other languages
English (en)
Inventor
Clapham Bruce
B Cox Phil
F Daanen Jerome
Gomtsyan Arthur
E Kort Michael
R Kym Philip
A Voight Eric
G Schmidt Robert
J Dart Michael
Gfesser Gregory
K Bayburt Erol
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of AR088511A1 publication Critical patent/AR088511A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Channel Selection Circuits, Automatic Tuning Circuits (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Steroid Compounds (AREA)

Abstract

Además, composiciones que comprenden dichos compuestos y métodos para el tratamiento de condiciones y trastornos usando dichos compuestos y composiciones. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) o una sal del mismo, donde: las instancias de Rᵃ y Rᵇ son en forma independiente entre sí hidrógeno, alquilo, haloalquilo, halógeno, OH, O(alquilo), o un grupo fenilo que está opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, haloalquilo, y halógeno; u es 0, 1, ó 2; X³ es O; X⁴ es una unión, X⁵ es (CH₂)ₙ, y n es 2; o X³ es O; X⁴ es (CH₂)ₘ, X⁵ es (CH₂)ₙ, m y n son cada uno 1; o X³ es O; X⁴ es (CH₂)ₘ, X⁵ es (CH₂)ₙ, m es 1, y n es 2; o X³ es O; X⁴ es una unión, X⁵ es (CH₂)ₙ, y n es 3; y X¹ es -OH y X² es hidrógeno; G¹ es arilo, heteroarilo, cicloalquilo, heterociclo, o cicloalquenilo; cada uno de los cuales está opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, halógeno, haloalquilo, ORᵍᶜ, N(Rᵍᶜ)₂, N(Rᵍᶜ)C(O)alquilo, heteroarilo, y heterociclo; las unidades heteroarilo y heterociclo en forma independiente entre sí no están sustituidas o están sustituidas con 1, 2, 3, 4, ó 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, O(alquilo), halógeno, y haloalquilo; y donde cada Rᵍᶜ es en forma independiente hidrógeno, alquilo, o haloalquilo; G² es G²ᵈ o -(CR¹ᵍR²ᵍ)ʳ-G²ᵈ donde: r es 1, 2, ó 3; R¹ᵍ y R²ᵍ son iguales o diferentes, y son en forma independiente entre sí hidrógeno, alquilo, halógeno, OR¹ᵍᶜ, N(R¹ᵍᶜ)₂, C(O)alquilo, o haloalquilo; donde cada R¹ᵍᶜ es en forma independiente hidrógeno, alquilo, o haloalquilo; G²ᵈ es arilo, heteroarilo, cicloalquilo, heterociclo, o cicloalquenilo, cada uno de los cuales está opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en Gᵈ, alquilo, alquenilo, alquinilo, halógeno, haloalquilo, -CN, -ORᶠ, -OC(O)Rᶠ, -OC(O)N(Rᶠ)₂, -S(O)₂Rᵉ, -S(O)₂N(Rᶠ)₂, -C(O)Rᶠ, -C(O)ORᶠ, -C(O)N(Rᶠ)₂, -N(Rᶠ)₂, -N(Rᶠ)C(O)Rᶠ, -N(Rᶠ)S(O)₂Rᵉ, -N(Rᶠ)C(O)O(Rᵉ), -N(Rᶠ)C(O)N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-Gᵈ, -(CR¹ᵃR¹ᵇ)q-ORᶠ, -(CR¹ᵃR¹ᵇ)q-OC(O)Rᶠ, -(CR¹ᵃR¹ᵇ)q-OC(O)N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-S(O)₂Rᵉ, -(CR¹ᵃR¹ᵇ)q-S(O)₂N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-C(O)Rᶠ, -(CR¹ᵃR¹ᵇ)q-C(O)ORᶠ, -(CR¹ᵃR¹ᵇ)q-C(O)N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)C(O)Rᶠ, -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)S(O)₂Rᵉ, -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)C(O)O(Rᵉ), -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)C(O)N(Rᶠ)₂, y -(CR¹ᵃR¹ᵇ)q-CN; R¹ᵃ y R¹ᵇ, son iguales o diferentes, y en cada caso son en forma independiente entre sí hidrógeno, halógeno, alquilo, o haloalquilo; cada instancia de Rᶠ es en forma independiente hidrógeno, alquilo, haloalquilo, Gᵈ, o -(CR¹ᵃR¹ᵇ)q-Gᵈ; cada instancia de Rᵉ es en forma independiente alquilo, haloalquilo, Gᵈ, o -(CR¹ᵃR¹ᵇ)q-Gᵈ; q, en cada caso, es en forma independiente 1, 2, ó 3; cada instancia de Gᵈ es en forma independiente arilo, heteroarilo, cicloalquilo, heterociclo, o cicloalquenilo; y está opcionalmente sustituido en cada caso con 1, 2, 3, 4, ó 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, halógeno, haloalquilo, -CN, -ORʲ, -OC(O)Rʲ, -OC(O)N(Rʲ)₂, -S(O)₂Rᵏ, -S(O)₂N(Rʲ)₂, -C(O)Rʲ, -C(O)ORʲ, -C(O)N(Rʲ)₂, -N(Rʲ)₂, -N(Rʲ)C(O)Rʲ, -N(Rʲ)S(O)₂Rᵏ, N(Rʲ)C(O)O(Rᵏ), -N(Rʲ)C(O)N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-ORʲ, -(CR¹ᵃR¹ᵇ)q-OC(O)Rʲ, -(CR¹ᵃR¹ᵇ)q-OC(O)N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-S(O)₂Rᵏ, -(CR¹ᵃR¹ᵇ)q-S(O)₂N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-C(O)Rʲ, -(CR¹ᵃR¹ᵇ)q-C(O)ORʲ, -(CR¹ᵃR¹ᵇ)q-C(O)N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-N(Rʲ)S(O)₂Rᵏ, -(CR¹ᵃR¹ᵇ)q-N(Rʲ)C(O)O(Rᵏ), -(CR¹ᵃR¹ᵇ)q-N(Rʲ)C(O)N(Rʲ)₂, y -(CR¹ᵃR¹ᵇ)q-CN; cada instancia de Rʲ es en forma independiente hidrógeno, alquilo, o haloalquilo; y cada instancia de Rᵏ es en forma independiente alquilo o haloalquilo.
ARP120103976A 2011-10-24 2012-10-24 Derivados heterociclicos como moduladores de trpv3 AR088511A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011001761 2011-10-24

Publications (1)

Publication Number Publication Date
AR088511A1 true AR088511A1 (es) 2014-06-18

Family

ID=47178922

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120103976A AR088511A1 (es) 2011-10-24 2012-10-24 Derivados heterociclicos como moduladores de trpv3
ARP120103975A AR088510A1 (es) 2011-10-24 2012-10-24 Moduladores de trpv3

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP120103975A AR088510A1 (es) 2011-10-24 2012-10-24 Moduladores de trpv3

Country Status (9)

Country Link
US (2) US8772500B2 (es)
EP (1) EP2771322A2 (es)
JP (1) JP2014530911A (es)
AR (2) AR088511A1 (es)
CA (1) CA2853097A1 (es)
MX (1) MX2014004979A (es)
TW (2) TW201323381A (es)
UY (2) UY34408A (es)
WO (2) WO2013062964A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013001612A (es) 2010-08-10 2013-07-05 Abbvie Inc Moduladores de trpv3 novedosos.
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
JP2014530911A (ja) 2011-10-24 2014-11-20 アッヴィ・インコーポレイテッド Ｔｒｐｖ３モジュレーターとしてのメタノール誘導体
US20180037528A1 (en) * 2015-02-27 2018-02-08 The Feinstein Institute For Medical Research Treatment method, compounds, and method of increasing trpv2 activity
NZ737451A (en) * 2015-05-20 2022-01-28 Integrative Res Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
FI3609868T3 (fi) 2017-03-13 2023-11-22 Raqualia Pharma Inc Tetrahydrokinoliinijohdannaisia P2X7-reseptorin antagonisteina
EP4580618A2 (en) * 2022-08-30 2025-07-09 Pannex Therapeutics Inc. Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914820A1 (de) 1989-05-05 1990-11-08 Basf Ag Neue pyridinderivate und ihre verwendung als fungizide
DE4318916A1 (de) 1993-06-07 1994-12-08 Bayer Ag Cyclobutylazole
GB9315808D0 (en) * 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
AU2720199A (en) 1998-02-03 1999-08-23 Boehringer Ingelheim Pharma Kg Five-membered, benzo-condensed heterocycles used as antithrombotic agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
WO2002022572A2 (en) * 2000-09-11 2002-03-21 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
EP1399558A2 (en) 2001-06-13 2004-03-24 Novartis AG Vanilloid receptor-related nucleic acids and polypeptides
CA2481320A1 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
NZ540328A (en) * 2002-11-06 2008-02-29 Amgen Inc Fused heterocyclic compounds
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7803790B2 (en) 2005-05-09 2010-09-28 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
CN101355946B (zh) 2005-11-04 2013-05-08 海德拉生物科学公司 调节trpv3功能的化合物
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
BRPI0810362A2 (pt) 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2217548A1 (en) 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
GEP20125709B (en) 2008-06-17 2012-12-10 Glenmark Pharmaceuticals Sa Chromane derivatives as trpv3 modulators
WO2009152647A1 (zh) * 2008-06-20 2009-12-23 江苏恩华药业股份有限公司 芳烷基哌啶衍生物及其在制备镇痛、镇静药物中的应用
US8318928B2 (en) 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
KR101469395B1 (ko) 2010-07-12 2014-12-04 에프. 호프만-라 로슈 아게 1-하이드록시이미노-3-페닐-프로판
MX2013001612A (es) * 2010-08-10 2013-07-05 Abbvie Inc Moduladores de trpv3 novedosos.
JP2014530911A (ja) 2011-10-24 2014-11-20 アッヴィ・インコーポレイテッド Ｔｒｐｖ３モジュレーターとしてのメタノール誘導体

Also Published As

Publication number Publication date
TW201323381A (zh) 2013-06-16
US8772500B2 (en) 2014-07-08
WO2013062964A3 (en) 2013-08-15
MX2014004979A (es) 2014-10-24
EP2771322A2 (en) 2014-09-03
AR088510A1 (es) 2014-06-18
CA2853097A1 (en) 2013-05-02
US20140080803A1 (en) 2014-03-20
UY34407A (es) 2013-05-31
TW201323408A (zh) 2013-06-16
WO2013062966A2 (en) 2013-05-02
US8772499B2 (en) 2014-07-08
JP2014530911A (ja) 2014-11-20
WO2013062966A3 (en) 2013-08-22
UY34408A (es) 2013-05-31
US20130131036A1 (en) 2013-05-23
WO2013062964A2 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
AR088511A1 (es) Derivados heterociclicos como moduladores de trpv3
AR089527A1 (es) Inhibidores de bromodominios
AR118312A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
ES2722048T3 (es) Compuestos de triazolopirimidina y usos de los mismos
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR091023A1 (es) Inhibidores del nampt
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR096757A1 (es) Inhibidores de bromodominios
CR20160478A (es) Composición de control de enfermedades de plantas y método para controlar enfermedades de plantas mediante su aplicación
AR093308A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
AR091022A1 (es) Inhibidores del nampt
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
PH12022552034A1 (en) Pyridone derivative having tetrahydropyranyl methyl group
AR072845A1 (es) 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas.
AR095422A1 (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
AR098647A1 (es) Inhibidores de serina / treonina cinasa
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
AR093057A1 (es) Inhibidores de la syk

Legal Events

Date Code Title Description
FA Abandonment or withdrawal